925206-65-1

Usage

Uses

Used in Oncology:
RRX-001 is used as an anticancer agent for selectively targeting and altering the tumor microenvironment, making it more susceptible to chemotherapy and radiation treatments. It increases the levels of nitric oxide (NO) and reactive oxygen species (ROS) within the tumor, weakening cancer cells and enhancing the effectiveness of traditional cancer therapies.
Used in Angiogenesis Inhibition:
RRX-001 is used as an angiogenesis inhibitor for preventing the formation of new blood vessels in tumors, thereby limiting their growth and metastasis. By inhibiting angiogenesis, RRX-001 can help control tumor progression and improve treatment outcomes for cancer patients.

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 125735-38-8 N-tert-butyl-3,3-dinitroazetidine 

Downstream Products

• 1429643-39-9 (R)-methyl 2-acetamido-3-(2-(3,3-dinitroazetidin-1-yl)-2-oxoethylthio)propanoate 

Relevant academic research and scientific papers

Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

After extensive screening of aerospace compounds in an effort to source a novel anticancer agent, RRx-001, a first-in-class dinitroazetidine small molecule, was selected for advancement into preclinical and clinical development. RRx-001 is a minimally tox

Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3,3-dinitroazetidine, a novel clinical anticancer candidate

An efficient process for synthesizing and isolating a new investigative anticancer agent, 1-bromoacetyl-3,3-dinitroazetidine, is described. The reaction entails a sequence of oxidative nitration followed by acylative dealkylation. The methods reported give 50-60-g batches of high-purity product without a designated purification step. The reaction conditions have been designed to mitigate the safety concerns associated with gem-dinitroazetidines. Some observations on the acylative dealkylation mechanism are discussed.

METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME

A method of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine (ABDNAZ) by reacting DNAZ with bromoacetyl bromide and boron trifluoride etherate to produce a mixture comprising ABDNAZ and a salt of DNAZ. Water and a solvent are added to the mixture to form an organic phase comprising the ABDNAZ and an aqueous phase comprising the salt of DNAZ. The organic phase and the aqueous phase are separated to produce an ABDNAZ/solvent solution comprising the ABDNAZ and the aqueous phase comprising the salt of DNAZ. A nonsolvent is added to the ABDNAZ/solvent solution to produce an ABDNAZ/solvent/nonsolvent mixture. The ABDNAZ is subsequently recovered. A composition comprising ABDNAZ is also disclosed.

CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.